New hope for Hard-to-Treat cancers: experimental PARP inhibitor enters human trials
Disease control
Recruiting now
This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…
Phase: PHASE1, PHASE2 • Sponsor: Acerand Therapeutics (Shanghai) Limited • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC